At a glance
- Originator Abbott Laboratories
- Class Antibacterials
- Mechanism of Action DNA gyrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
- 21 May 2001 Profile reviewed but no significant changes made
- 21 May 2001 No-Development-Reported for Bacterial infections in USA (Unknown route)